15 Drugs Added to Medicare Price Negotiations

Botox, Trulicity among treatments covered under expanded program

Jan. 28, 2026 at 11:39am

Got story updates? Submit your updates here. ›

The Trump administration has kicked off another round of Medicare drug price negotiations, this time including treatments administered in doctors' offices such as those for Type 2 diabetes, HIV, cancer and arthritis. The 15 drugs chosen represent the highest-spending medications on a list of 50 top negotiation-eligible drugs, accounting for about $27 billion in Medicare Part B and D spending. The negotiated prices will take effect in 2028 and aim to significantly reduce out-of-pocket costs for millions of Medicare beneficiaries.

Why it matters

This expansion of the Medicare drug price negotiation program, a key pillar of the Biden administration's Inflation Reduction Act, marks the first time treatments administered in doctors' offices have been included. The move aims to rein in overpayments in the privately run Medicare program, which has faced allegations of aggressive coding practices by insurers to illegally drive up revenue.

The details

The 15 drugs selected for the 2028 negotiations cover a range of treatments, including Botox for muscle spasms, Trulicity for Type 2 diabetes, and Biktarvy for HIV. While the negotiated prices are expected to significantly reduce out-of-pocket costs for Medicare beneficiaries, analysts estimate that for 14 of the 15 drugs, Medicare revenue exposed to the negotiations represents only 0% to 3% of the companies' worldwide 2027 sales, with the exception of Gilead's Biktarvy, which accounts for around 8% of the company's estimated 2027 revenue.

  • The negotiated prices for the 15 drugs will take effect in 2028.
  • The drugs were selected from a list of the 50 top negotiation-eligible drugs, based on spending between November 2024 and October 2025.

The players

Trump administration

The current presidential administration, which is kicking off another round of Medicare drug price negotiations.

Centers for Medicare and Medicaid Services

The federal agency that released the list of 50 top negotiation-eligible drugs and the details on the 15 drugs selected for the 2028 negotiations.

Gilead

The pharmaceutical company that makes the HIV treatment Biktarvy, which accounts for a significant portion of its estimated 2027 revenue.

Eli Lilly

The pharmaceutical company that makes the diabetes treatment Trulicity, which was selected for the 2028 Medicare price negotiations.

Got photos? Submit your photos here. ›

What they’re saying

“We all feel the pinch of how expensive health care is, and it is a real waste of government resources when entities involved in Medicare Advantage are getting paid more than they should get paid like that. Those are our health care dollars, and they should go where they're needed, right?”

— Hamsa Mahendranathan, Attorney (CNBC)

What’s next

The negotiated prices for the 15 drugs selected will take effect in 2028, and the Trump administration has signaled it could take a tougher approach to insurers in the Medicare Advantage system, proposing nearly flat payment rates for next year and moving to crack down on aggressive coding practices.

The takeaway

The expansion of the Medicare drug price negotiation program to include treatments administered in doctors' offices represents a significant step in the Biden administration's efforts to rein in healthcare costs and address allegations of overpayments and fraud in the Medicare Advantage system.